{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Various+Advanced+Cancer", "query": { "condition": "Various Advanced Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Various+Advanced+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T16:03:33.806Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05676931", "title": "Study With Various Immunotherapy Treatments in Participants With Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Platinum-Based Doublet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2023-02-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • Hollywood, Florida + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "The Villages", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05676931" }, { "nct_id": "NCT02387996", "title": "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2015-03-09", "completion_date": "2021-11-12", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Duarte, California • San Francisco, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387996" }, { "nct_id": "NCT02632409", "title": "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 709, "start_date": "2016-03-22", "completion_date": "2027-05-27", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 33, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632409" }, { "nct_id": "NCT03143153", "title": "A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 970, "start_date": "2017-06-29", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 16, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03143153" }, { "nct_id": "NCT03130959", "title": "A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 166, "start_date": "2017-06-12", "completion_date": "2022-01-17", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 14, "location_summary": "Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03130959" }, { "nct_id": "NCT01986218", "title": "Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "BMS-986115", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2013-11", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01986218" }, { "nct_id": "NCT07664397", "title": "Imaging Study of [89Zr]DFO-YS5 for Cancer Detection", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Nerve Sheath Tumor", "Nerve Sheath Tumors", "Solid Tumor Malignancies", "Solid Tumor Cancer", "Solid Tumor Neoplasms", "Advanced Solid Tumor", "Bladder Neoplasm", "Nerve Sheath Neoplasms", "Nerve Sheath Tumor, Nos", "Solid Tumor, Adult", "Solid Carcinoma" ], "interventions": [ { "name": "[89Zr]DFO-YS5", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI)", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography (PET)-Computerized tomography (CT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Robert Flavell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-08-01", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07664397" }, { "nct_id": "NCT03335540", "title": "An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Cabiralizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "IDO1 Inhibitor", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-05-07", "completion_date": "2021-08-25", "has_results": false, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 4, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03335540" }, { "nct_id": "NCT00046423", "title": "A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Metastases, Neoplasm" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-11-25", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046423" }, { "nct_id": "NCT01700049", "title": "Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "vismodegib (150 mg PO daily)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2013-01-14", "completion_date": "2018-07-03", "has_results": true, "last_update_posted_date": "2019-05-23", "last_synced_at": "2026-06-25T16:03:33.806Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01700049" } ] }